Ximelagatran (Exanta or Exarta, H 376/95) is an anticoagulant that has been investigated extensively as a replacement for warfarin that would overcome the problematic dietary, drug interaction, and monitoring issues associated with warfarin therapy.

PropertyValue
dbpedia-owl:Drug/atcPrefix
  • B01
dbpedia-owl:Drug/atcSuffix
  • AE05
dbpedia-owl:Drug/casNumber
  • 192939-46-1
dbpedia-owl:Drug/iupacName
  • ethyl 2-[[(1R)-1-cyclohexyl-2-
    [(2S)-2-[[4-(N'-hydroxycarbamimidoyl)
    phenyl]methylcarbamoyl]azetidin-1-yl]-
    2-oxo-ethyl]amino]acetate
dbpedia-owl:Drug/pubchem
  • 5478933
dbpedia-owl:atcPrefix
  • B01
dbpedia-owl:atcSuffix
  • AE05
dbpedia-owl:casNumber
  • 192939-46-1
dbpedia-owl:iupacName
  • ethyl 2-[[(1R)-1-cyclohexyl-2-
    [(2S)-2-[[4-(N'-hydroxycarbamimidoyl)
    phenyl]methylcarbamoyl]azetidin-1-yl]-
    2-oxo-ethyl]amino]acetate
dbpedia-owl:pubchem
  • 5478933
dbpedia-owl:thumbnail
dbpprop:abstract
  • Ximelagatran (Exanta or Exarta, H 376/95) is an anticoagulant that has been investigated extensively as a replacement for warfarin that would overcome the problematic dietary, drug interaction, and monitoring issues associated with warfarin therapy. In 2006, its manufacturer AstraZeneca announced that it would withdraw pending applications for marketing approval after reports of hepatotoxicity (liver damage) during trials, and discontinue its distribution in countries where the drug had been approved (Germany, Portugal, Sweden, Finland, Norway, Iceland, Austria, Denmark, France, Switzerland, Argentina and Brazil).
  • Le ximélagatran(usage oral) était un médicament anticoagulant, prodrogue du mélagatran (usage sous-cutané). Le 14 février 2006, ce médicament a été retiré du marché au niveau mondial.. Son producteur voit en lui un remplaçant des anti-vitamines K, soumis aux aléas de la nutrition, de l'interaction médicamenteuse, et du monitoring (suivi sanguin).
dbpprop:atcPrefix
  • B01
dbpprop:atcSuffix
  • AE05
dbpprop:bioavailability
  • 20
dbpprop:c
  • 24 (xsd:integer)
dbpprop:casNumber
  • 192939-46-1
dbpprop:eliminationHalfLife
  • 3-5h
dbpprop:excretion
  • Renal (80%)
dbpprop:h
  • 35 (xsd:integer)
dbpprop:hasPhotoCollection
dbpprop:iupacName
  • ethyl 2-[[(1R)-1-cyclohexyl-2-
    [(2S)-2-[[4-(N'-hydroxycarbamimidoyl)
    phenyl]methylcarbamoyl]azetidin-1-yl]-
    2-oxo-ethyl]amino]acetate
dbpprop:legalStatus
  • Rx only/POM
dbpprop:metabolism
  • None
dbpprop:molecularWeight
  • 474 (429 after conversion)
dbpprop:n
  • 5 (xsd:integer)
dbpprop:o
  • 5 (xsd:integer)
dbpprop:pregnancyCategory
  • uncategorised
dbpprop:pubchem
  • 5478933 (xsd:integer)
dbpprop:routesOfAdministration
  • Oral
dbpprop:width
  • 189 (xsd:integer)
dbpprop:wikiPageUsesTemplate
rdf:type
rdfs:comment
  • Ximelagatran (Exanta or Exarta, H 376/95) is an anticoagulant that has been investigated extensively as a replacement for warfarin that would overcome the problematic dietary, drug interaction, and monitoring issues associated with warfarin therapy.
  • Le ximélagatran(usage oral) était un médicament anticoagulant, prodrogue du mélagatran (usage sous-cutané). Le 14 février 2006, ce médicament a été retiré du marché au niveau mondial.. Son producteur voit en lui un remplaçant des anti-vitamines K, soumis aux aléas de la nutrition, de l'interaction médicamenteuse, et du monitoring (suivi sanguin).
rdfs:label
  • Ximelagatran
  • Ximélagatran
owl:sameAs
skos:subject
foaf:depiction
foaf:page
is dbpprop:redirect of
is owl:sameAs of